1
|
El Sadda RR, Eissa MS, Elafndi RK, Moawed EA, El-Zahed MM, Saad HR. Synthesis and biological evaluation of titanium dioxide/thiopolyurethane composite: anticancer and antibacterial effects. BMC Chem 2024; 18:35. [PMID: 38368376 PMCID: PMC10874576 DOI: 10.1186/s13065-024-01138-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Accepted: 02/06/2024] [Indexed: 02/19/2024] Open
Abstract
Nanocomposites incorporating titanium dioxide (TiO2) have a significant potential for various industrial and medical applications. These nanocomposites exhibit selectivity as antimicrobial and anticancer agents. Antimicrobial activity is crucial for medical uses, including applications in food processing, packaging, and surgical instruments. Additionally, these nanocomposites exhibit selectivity as anticancer agents. A stable nanocomposite as a new anticancer and antibacterial chemical was prepared by coupling titanium dioxide nanoparticles with a polyurethane foam matrix through the thiourea group. The titanium dioxide/thiopolyurethane nanocomposite (TPU/TiO2) was synthesized from low-cost Ilmenite ore and commercial polyurethane foam. EDX analysis was used to determine the elemental composition of the titanium dioxide (TiO2) matrix. TiO2NPs were synthesized and were characterized using TEM, XRD, IR, and UV-Vis spectra. TiO2NPs and TPU foam formed a novel composite. The MTT assay assessed Cisplatin and HepG-2 and MCF-7 cytotoxicity in vitro. Its IC50 values for HepG-2 and MCF-7 were 122.99 ± 4.07 and 201.86 ± 6.82 µg/mL, respectively. The TPU/TiO2 exhibits concentration-dependent cytotoxicity against MCF-7 and HepG-2 cells in vitro. The selective index was measured against both cell lines; it showed its safety against healthy cells. Agar well-diffusion exhibited good inhibition zones against Escherichia coli (12 mm), Bacillus cereus (10 mm), and Aspergillus niger (19 mm). TEM of TPU/TiO2-treated bacteria showed ultrastructure changes, including plasma membrane detachment from the cell wall, which caused lysis and bacterial death. TPU/TiO2 can treat cancer and inhibit microbes in dentures and other items. Also, TPU/TiO2 inhibits E. coli, B. cereus, and A. niger microbial strains.
Collapse
Affiliation(s)
- Rana R El Sadda
- Chemistry Department, Faculty of Science, Damietta University, P.O. Box 34517, New Damietta, Egypt.
| | - Mai S Eissa
- Chemistry Department, Faculty of Science, Damietta University, P.O. Box 34517, New Damietta, Egypt
| | - Rokaya K Elafndi
- Chemistry Department, Faculty of Science, Damietta University, P.O. Box 34517, New Damietta, Egypt
| | - Elhossein A Moawed
- Chemistry Department, Faculty of Science, Damietta University, P.O. Box 34517, New Damietta, Egypt
| | - Mohamed M El-Zahed
- Botany and Microbiology Department, Faculty of Science, Damietta University, New Damietta, Egypt
| | - Hoda R Saad
- Geology Department, Faulty of Science, Damietta University, New Damietta, Egypt
| |
Collapse
|
2
|
Bonelli J, Velasco-de Andrés M, Isidro N, Bayó C, Chumillas S, Carrillo-Serradell L, Casadó-Llombart S, Mok C, Benítez-Ribas D, Lozano F, Rocas J, Marchán V. Novel Tumor-Targeted Self-Nanostructured and Compartmentalized Water-in-Oil-in-Water Polyurethane-Polyurea Nanocapsules for Cancer Theragnosis. Pharmaceutics 2022; 15:pharmaceutics15010058. [PMID: 36678687 PMCID: PMC9862617 DOI: 10.3390/pharmaceutics15010058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Revised: 11/26/2022] [Accepted: 12/20/2022] [Indexed: 12/28/2022] Open
Abstract
Encapsulation of water-soluble bioactive compounds for enabling specific accumulation in tumor locations, while avoiding premature clearance and/or degradation in the bloodstream, is one of the main hallmarks in nanomedicine, especially that of NIR fluorescent probes for cancer theragnosis. The herein reported technology furnishes water-dispersible double-walled polyurethane-polyurea hybrid nanocapsules (NCs) loaded with indocyanine green (ICG-NCs), using a versatile and highly efficient one-pot and industrially scalable synthetic process based on the use of two different prepolymers to set up the NCs walls. Flow cytometry and confocal microscopy confirmed that both ICG-loaded NCs internalized in monocyte-derived dendritic cells (moDCs). The in vivo analysis of xenograft A375 mouse melanoma model revealed that amphoteric functionalization of NCs' surface promotes the selective accumulation of ICG-NCs in tumor tissues, making them promising agents for a less-invasive theragnosis of cancer.
Collapse
Affiliation(s)
- Joaquín Bonelli
- Departament de Química Inorgànica i Orgànica, Secció de Química Orgànica, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona (UB), Martí i Franquès 1-11, E-08028 Barcelona, Spain
- Nanobiotechnological Polymers Division Ecopol Tech, S.L., El Foix Business Park, Indústria 7, L'Arboç del Penedès, E-43720 Tarragona, Spain
| | - María Velasco-de Andrés
- Immunoreceptors del Sistema Innat i Adaptatiu, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló 149-151, E-08036 Barcelona, Spain
| | - Neus Isidro
- Nanobiotechnological Polymers Division Ecopol Tech, S.L., El Foix Business Park, Indústria 7, L'Arboç del Penedès, E-43720 Tarragona, Spain
| | - Cristina Bayó
- Servei d'Immunologia, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Villarroel 170, E-08036 Barcelona, Spain
| | - Sergi Chumillas
- Departament de Química Inorgànica i Orgànica, Secció de Química Orgànica, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona (UB), Martí i Franquès 1-11, E-08028 Barcelona, Spain
| | - Laura Carrillo-Serradell
- Immunoreceptors del Sistema Innat i Adaptatiu, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló 149-151, E-08036 Barcelona, Spain
| | - Sergi Casadó-Llombart
- Immunoreceptors del Sistema Innat i Adaptatiu, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló 149-151, E-08036 Barcelona, Spain
| | - Cheryl Mok
- Servei d'Immunologia, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Villarroel 170, E-08036 Barcelona, Spain
| | - Daniel Benítez-Ribas
- Servei d'Immunologia, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Villarroel 170, E-08036 Barcelona, Spain
| | - Francisco Lozano
- Immunoreceptors del Sistema Innat i Adaptatiu, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló 149-151, E-08036 Barcelona, Spain
- Servei d'Immunologia, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Villarroel 170, E-08036 Barcelona, Spain
- Departament de Biomedicina, Universitat de Barcelona (UB), Villarroel 170, E-08036 Barcelona, Spain
| | - Josep Rocas
- Nanobiotechnological Polymers Division Ecopol Tech, S.L., El Foix Business Park, Indústria 7, L'Arboç del Penedès, E-43720 Tarragona, Spain
| | - Vicente Marchán
- Departament de Química Inorgànica i Orgànica, Secció de Química Orgànica, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona (UB), Martí i Franquès 1-11, E-08028 Barcelona, Spain
| |
Collapse
|
3
|
Zhou Y, Hou D, Marigo CC, Bonelli J, Rocas P, Cheng F, Yang X, Rocas J, Hamberg NM, Han J. Redox-responsive polyurethane-polyurea nanoparticles targeting to aortic endothelium and atherosclerosis. iScience 2022; 25:105390. [PMID: 36345337 PMCID: PMC9636043 DOI: 10.1016/j.isci.2022.105390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 07/23/2022] [Accepted: 10/14/2022] [Indexed: 11/09/2022] Open
Abstract
Aortic endothelial cell dysfunction is an early trigger of atherosclerosis, the major cause of the cardiovascular disease (CVD). Nanomedicines targeting vascular endothelium and lesions hold great promise as therapeutic solutions to vascular disorders. This study investigates the vascular delivery efficacy of polyurethane-polyurea nanocapsules (Puua-NCs) with pH-synchronized shell cationization and redox-triggered release. Fluorescent lipophilic dye DiI was encapsulated into Puua-NCs of variable sizes and concentrations. In vitro cellular uptake studies with human aortic endothelial cells showed that these Puua-NCs were taken up by cells in a dose-dependent manner. In apolipoprotein E-deficient mice fed a Western diet, a model of atherosclerosis, circulating Puua-NCs were stable and accumulated in aortic endothelium and lesions within 24 hours after intravenous administration. Treatment with thiol-reducing and oxidizing reagents disrupted the disulfide bonds on the surface of internalized NCs, triggering disassembly and intracellular cargo release. Ultimately, Puua-NCs are a potential redox-controllable cardiovascular drug delivery system.
Collapse
Affiliation(s)
- Yuxiang Zhou
- Vascular Biology Section, Evans Department of Medicine, Whitaker Cardiovascular Institute, Boston University School of Medicine, 650 Albany St. X 729, Boston, MA, USA
| | - David Hou
- Vascular Biology Section, Evans Department of Medicine, Whitaker Cardiovascular Institute, Boston University School of Medicine, 650 Albany St. X 729, Boston, MA, USA
| | | | - Joaquín Bonelli
- Nanobiotechnological Polymers Division, Ecopol Tech S.L., L’Arboc, Spain
| | - Pau Rocas
- Nanobiotechnological Polymers Division, Ecopol Tech S.L., L’Arboc, Spain
| | - Fangzhou Cheng
- Vascular Biology Section, Evans Department of Medicine, Whitaker Cardiovascular Institute, Boston University School of Medicine, 650 Albany St. X 729, Boston, MA, USA
| | - Xiaoqiu Yang
- Vascular Biology Section, Evans Department of Medicine, Whitaker Cardiovascular Institute, Boston University School of Medicine, 650 Albany St. X 729, Boston, MA, USA
| | - Josep Rocas
- Nanobiotechnological Polymers Division, Ecopol Tech S.L., L’Arboc, Spain
| | - Naomi M. Hamberg
- Vascular Biology Section, Evans Department of Medicine, Whitaker Cardiovascular Institute, Boston University School of Medicine, 650 Albany St. X 729, Boston, MA, USA
| | - Jingyan Han
- Vascular Biology Section, Evans Department of Medicine, Whitaker Cardiovascular Institute, Boston University School of Medicine, 650 Albany St. X 729, Boston, MA, USA
| |
Collapse
|
4
|
Fernández Y, Movellan J, Foradada L, Giménez V, García‐Aranda N, Mancilla S, Armiñán A, Borgos SE, Hyldbakk A, Bogdanska A, Gobbo OL, Prina‐Mello A, Ponti J, Calzolai L, Zagorodko O, Gallon E, Niño‐Pariente A, Paul A, Schwartz Jr S, Abasolo I, Vicent MJ. In Vivo Antitumor and Antimetastatic Efficacy of a Polyacetal-Based Paclitaxel Conjugate for Prostate Cancer Therapy. Adv Healthc Mater 2022; 11:e2101544. [PMID: 34706167 DOI: 10.1002/adhm.202101544] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 09/25/2021] [Indexed: 12/12/2022]
Abstract
Prostate cancer (PCa), one of the leading causes of cancer-related deaths, currently lacks effective treatment for advanced-stage disease. Paclitaxel (PTX) is a highly active chemotherapeutic drug and the first-line treatment for PCa; however, conventional PTX formulation causes severe hypersensitivity reactions and limits PTX use at high concentrations. In the pursuit of high molecular weight, biodegradable, and pH-responsive polymeric carriers, one conjugates PTX to a polyacetal-based nanocarrier to yield a tert-Ser-PTX polyacetal conjugate. tert-Ser-PTX conjugate provides sustained release of PTX over 2 weeks in a pH-responsive manner while also obtaining a degree of epimerization of PTX to 7-epi-PTX. Serum proteins stabilize tert-Ser-PTX, with enhanced stability in human serum versus PBS (pH 7.4). In vitro efficacy assessments in PCa cells demonstrate IC50 values above those for the free form of PTX due to the differential cell trafficking modes; however, in vivo tolerability assays demonstrate that tert-Ser-PTX significantly reduces the systemic toxicities associated with free PTX treatment. tert-Ser-PTX also effectively inhibits primary tumor growth and hematologic, lymphatic, and coelomic dissemination, as confirmed by in vivo and ex vivo bioluminescence imaging and histopathological evaluations in mice carrying orthotopic LNCaP tumors. Overall, the results suggest the application of tert-Ser-PTX as a robust antitumor/antimetastatic treatment for PCa.
Collapse
Affiliation(s)
- Yolanda Fernández
- Functional Validation & Preclinical Research (FVPR) CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Drug Delivery & Targeting Group CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER‐BBN) Barcelona 08035 Spain
| | - Julie Movellan
- Polymer Therapeutics Laboratory. Centro de Investigación Príncipe Felipe. Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - Laia Foradada
- Functional Validation & Preclinical Research (FVPR) CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Drug Delivery & Targeting Group CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER‐BBN) Barcelona 08035 Spain
| | - Vanessa Giménez
- Polymer Therapeutics Laboratory. Centro de Investigación Príncipe Felipe. Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - Natalia García‐Aranda
- Functional Validation & Preclinical Research (FVPR) CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Drug Delivery & Targeting Group CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER‐BBN) Barcelona 08035 Spain
| | - Sandra Mancilla
- Functional Validation & Preclinical Research (FVPR) CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Drug Delivery & Targeting Group CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER‐BBN) Barcelona 08035 Spain
| | - Ana Armiñán
- Polymer Therapeutics Laboratory. Centro de Investigación Príncipe Felipe. Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - Sven Even Borgos
- Department of Biotechnology and Nanomedicine SINTEF Industry Trondheim NO‐7465 Norway
| | - Astrid Hyldbakk
- Department of Biotechnology and Nanomedicine SINTEF Industry Trondheim NO‐7465 Norway
| | - Anna Bogdanska
- Laboratory for Biological Characterization of Advanced Materials (LBCAM) Trinity Translational Medicine Institute Trinity College Dublin Dublin D08 W9RT Ireland
- Trinity St James's Cancer Institute Trinity College Dublin the University of Dublin Dublin D08 W9RT Ireland
| | - Oliviero L. Gobbo
- Trinity St James's Cancer Institute Trinity College Dublin the University of Dublin Dublin D08 W9RT Ireland
- School of Pharmacy and Pharmaceutical Sciences Trinity College Dublin Dublin D02 R590 Ireland
| | - Adriele Prina‐Mello
- Laboratory for Biological Characterization of Advanced Materials (LBCAM) Trinity Translational Medicine Institute Trinity College Dublin Dublin D08 W9RT Ireland
- Trinity St James's Cancer Institute Trinity College Dublin the University of Dublin Dublin D08 W9RT Ireland
| | - Jessica Ponti
- European Commission Joint Research Centre (JRC) via Fermi 2749 Ispra 21027 Italy
| | - Luigi Calzolai
- European Commission Joint Research Centre (JRC) via Fermi 2749 Ispra 21027 Italy
| | - Oleksandr Zagorodko
- Polymer Therapeutics Laboratory. Centro de Investigación Príncipe Felipe. Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - Elena Gallon
- Polymer Therapeutics Laboratory. Centro de Investigación Príncipe Felipe. Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - Amaya Niño‐Pariente
- Polymer Therapeutics Laboratory. Centro de Investigación Príncipe Felipe. Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - Alison Paul
- School of Chemistry Cardiff University Main Building, Park Place Cardiff CF10 3AT UK
| | - Simó Schwartz Jr
- Drug Delivery & Targeting Group CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER‐BBN) Barcelona 08035 Spain
| | - Ibane Abasolo
- Functional Validation & Preclinical Research (FVPR) CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Drug Delivery & Targeting Group CIBBIM‐Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain
- Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER‐BBN) Barcelona 08035 Spain
| | - María J. Vicent
- Polymer Therapeutics Laboratory. Centro de Investigación Príncipe Felipe. Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| |
Collapse
|
5
|
Multi-Smart and Scalable Bioligands-Free Nanomedical Platform for Intratumorally Targeted Tambjamine Delivery, a Difficult to Administrate Highly Cytotoxic Drug. Biomedicines 2021; 9:biomedicines9050508. [PMID: 34064518 PMCID: PMC8147975 DOI: 10.3390/biomedicines9050508] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 04/18/2021] [Accepted: 04/26/2021] [Indexed: 01/05/2023] Open
Abstract
Cancer is one of the leading causes of mortality worldwide due, in part, to limited success of some current therapeutic approaches. The clinical potential of many promising drugs is restricted by their systemic toxicity and lack of selectivity towards cancer cells, leading to insufficient drug concentration at the tumor site. To overcome these hurdles, we developed a novel drug delivery system based on polyurea/polyurethane nanocapsules (NCs) showing pH-synchronized amphoteric properties that facilitate their accumulation and selectivity into acidic tissues, such as tumor microenvironment. We have demonstrated that the anticancer drug used in this study, a hydrophobic anionophore named T21, increases its cytotoxic activity in acidic conditions when nanoencapsulated, which correlates with a more efficient cellular internalization. A biodistribution assay performed in mice has shown that the NCs are able to reach the tumor and the observed systemic toxicity of the free drug is significantly reduced in vivo when nanoencapsulated. Additionally, T21 antitumor activity is preserved, accompanied by tumor mass reduction compared to control mice. Altogether, this work shows these NCs as a potential drug delivery system able to reach the tumor microenvironment, reducing the undesired systemic toxic effects. Moreover, these nanosystems are prepared under scalable methodologies and straightforward process, and provide tumor selectivity through a smart mechanism independent of targeting ligands.
Collapse
|
6
|
Du G, Hu J, Zhou J, Wang G, Guan S, Liu H, Geng M, Lü C, Ming Y, Qu J. The study on the mechanical properties of PU/MF double shell self-healing microcapsules. Chin J Chem Eng 2020. [DOI: 10.1016/j.cjche.2020.03.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Long Y, An J, Xie X. CO2-releasing blowing agents from modified polyethylenimines slightly consume isocyanate groups while foaming polyurethanes. ARAB J CHEM 2020. [DOI: 10.1016/j.arabjc.2018.10.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
8
|
Nanomaterials for direct and indirect immunomodulation: A review of applications. Eur J Pharm Sci 2020; 142:105139. [DOI: 10.1016/j.ejps.2019.105139] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Revised: 10/14/2019] [Accepted: 11/03/2019] [Indexed: 01/03/2023]
|
9
|
Rocas P, Fernández Y, García-Aranda N, Foradada L, Calvo P, Avilés P, Guillén MJ, Schwartz S, Rocas J, Albericio F, Abasolo I. Improved pharmacokinetic profile of lipophilic anti-cancer drugs using ανβ3-targeted polyurethane-polyurea nanoparticles. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2017; 14:257-267. [PMID: 29127040 DOI: 10.1016/j.nano.2017.10.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Revised: 09/04/2017] [Accepted: 10/20/2017] [Indexed: 02/06/2023]
Abstract
Glutathione degradable polyurethane-polyurea nanoparticles (PUUa NP) with a disulfide-rich multiwalled structure and a cyclic RGD peptide as a targeting moiety were synthesized, incorporating a very lipophilic chemotherapeutic drug named Plitidepsin. In vitro studies indicated that encapsulated drug maintained and even improved its cytotoxic activity while in vivo toxicity studies revealed that the maximum tolerated dose (MTD) of Plitidepsin could be increased three-fold after encapsulation. We also found that pharmacokinetic parameters such as maximum concentration (Cmax), area under the curve (AUC) and plasma half-life were significantly improved for Plitidepsin loaded in PUUa NP. Moreover, biodistribution assays in mice showed that RGD-decorated PUUa NP accumulate less in spleen and liver than non-targeted conjugates, suggesting that RGD-decorated nanoparticles avoid sequestration by macrophages from the reticuloendothelial system. Overall, our results indicate that polyurethane-polyurea nanoparticles represent a very valuable nanoplatform for the delivery of lipophilic drugs by improving their toxicological, pharmacokinetic and whole-body biodistribution profiles.
Collapse
Affiliation(s)
- Pau Rocas
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain; Nanobiotechnological Polymers Division, Ecopol Tech S.L., L'Arboç, Spain
| | - Yolanda Fernández
- Functional Validation & Preclinical Research (FVPR), Drug Delivery and Targeting Group, CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain
| | - Natalia García-Aranda
- Functional Validation & Preclinical Research (FVPR), Drug Delivery and Targeting Group, CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain
| | - Laia Foradada
- Functional Validation & Preclinical Research (FVPR), Drug Delivery and Targeting Group, CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain
| | - Pilar Calvo
- PharmaMar S.A., Colmenar Viejo, Madrid, Spain
| | | | | | - Simó Schwartz
- Functional Validation & Preclinical Research (FVPR), Drug Delivery and Targeting Group, CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain
| | - Josep Rocas
- Nanobiotechnological Polymers Division, Ecopol Tech S.L., L'Arboç, Spain
| | - Fernando Albericio
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain; Department of Organic Chemistry, University of Barcelona, Barcelona, Spain; School of Chemistry & Physics, University of Kwazulu-Natal, Durban, South Africa
| | - Ibane Abasolo
- Functional Validation & Preclinical Research (FVPR), Drug Delivery and Targeting Group, CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.
| |
Collapse
|
10
|
Giannotti MI, Abasolo I, Oliva M, Andrade F, García-Aranda N, Melgarejo M, Pulido D, Corchero JL, Fernández Y, Villaverde A, Royo M, García-Parajo MF, Sanz F, Schwartz S. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS APPLIED MATERIALS & INTERFACES 2016; 8:25741-25752. [PMID: 27610822 DOI: 10.1021/acsami.6b08356] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Lysosomal storage disorders are currently treated by enzyme replacement therapy (ERT) through the direct administration of the unprotected recombinant protein to the patients. Herein we present an ionically cross-linked polyelectrolyte complex (PEC) composed of trimethyl chitosan (TMC) and α-galactosidase A (GLA), the defective enzyme in Fabry disease, with the capability of directly targeting endothelial cells by incorporating peptide ligands containing the RGD sequence. We assessed the physicochemical properties, cytotoxicity, and hemocompatibility of RGD-targeted and untargeted PECs, the uptake by endothelial cells and the intracellular activity of PECs in cell culture models of Fabry disease. Moreover, we also explored the effect of different freeze-drying procedures in the overall activity of the PECs. Our results indicate that the use of integrin-binding RGD moiety within the PEC increases their uptake and the efficacy of the GLA enzyme, while the freeze-drying allows the activity of the therapeutic protein to remain intact. Overall, these results highlight the potential of TMC-based PECs as a highly versatile and feasible drug delivery system for improving the ERT of lysosomal storage disorders.
Collapse
Affiliation(s)
- Marina I Giannotti
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , 28029 Madrid, Spain
- Nanoprobes & Nanoswitches, Institute for Bioengineering of Catalonia (IBEC) , Baldiri Reixac 10, 08028 Barcelona, Spain
- Physical Chemistry Department, Universitat de Barcelona , 08028 Barcelona, Spain
| | - Ibane Abasolo
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , 28029 Madrid, Spain
- CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona , 08035 Barcelona, Spain
| | - Mireia Oliva
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , 28029 Madrid, Spain
- Nanoprobes & Nanoswitches, Institute for Bioengineering of Catalonia (IBEC) , Baldiri Reixac 10, 08028 Barcelona, Spain
- Pharmacy and Pharmaceutical Technology Department, Universitat de Barcelona , 08028 Barcelona, Spain
| | - Fernanda Andrade
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , 28029 Madrid, Spain
- Nanoprobes & Nanoswitches, Institute for Bioengineering of Catalonia (IBEC) , Baldiri Reixac 10, 08028 Barcelona, Spain
- Pharmacy and Pharmaceutical Technology Department, Universitat de Barcelona , 08028 Barcelona, Spain
- Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto , 4050-313 Porto, Portugal
| | - Natalia García-Aranda
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , 28029 Madrid, Spain
- CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona , 08035 Barcelona, Spain
| | - Marta Melgarejo
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , 28029 Madrid, Spain
- Combinatorial Chemistry Unit, Barcelona Science Park , Baldiri Reixac 10, 08028 Barcelona, Spain
| | - Daniel Pulido
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , 28029 Madrid, Spain
- Combinatorial Chemistry Unit, Barcelona Science Park , Baldiri Reixac 10, 08028 Barcelona, Spain
| | - José L Corchero
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , 28029 Madrid, Spain
- Institut de Biotecnologia i de Biomedicina and Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona , Bellaterra, 08193 Cerdanyola del Vallès, Spain
| | - Yolanda Fernández
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , 28029 Madrid, Spain
- CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona , 08035 Barcelona, Spain
| | - Antonio Villaverde
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , 28029 Madrid, Spain
- Institut de Biotecnologia i de Biomedicina and Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona , Bellaterra, 08193 Cerdanyola del Vallès, Spain
| | - Miriam Royo
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , 28029 Madrid, Spain
- Combinatorial Chemistry Unit, Barcelona Science Park , Baldiri Reixac 10, 08028 Barcelona, Spain
| | - María F García-Parajo
- Institut de Ciencies Fotoniques, The Barcelona Institute of Science and Technology , ICREA, Pg. Lluís Companys 23, 08010 Barcelona, Spain
| | - Fausto Sanz
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , 28029 Madrid, Spain
- Nanoprobes & Nanoswitches, Institute for Bioengineering of Catalonia (IBEC) , Baldiri Reixac 10, 08028 Barcelona, Spain
- Physical Chemistry Department, Universitat de Barcelona , 08028 Barcelona, Spain
| | - Simó Schwartz
- Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , 28029 Madrid, Spain
- CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona , 08035 Barcelona, Spain
| |
Collapse
|
11
|
Flórez-Grau G, Rocas P, Cabezón R, España C, Panés J, Rocas J, Albericio F, Benítez-Ribas D. Nanoencapsulated budesonide in self-stratified polyurethane-polyurea nanoparticles is highly effective in inducing human tolerogenic dendritic cells. Int J Pharm 2016; 511:785-93. [PMID: 27477102 DOI: 10.1016/j.ijpharm.2016.07.056] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2016] [Revised: 07/21/2016] [Accepted: 07/24/2016] [Indexed: 01/27/2023]
Abstract
The design of innovative strategies to selectively target cells, such antigen-presenting cells and dendritic cells, in vivo to induce immune tolerance is gaining interest and relevance for the treatment of immune-mediated diseases. A novel loaded-nanosystem strategy to generate tolerogenic dendritic cells (tol-DCs) was evaluated. Hence budesonide (BDS) was encapsulated in multiwalled polyurethane-polyurea nanoparticles (PUUa NPs-BDS) based on self-stratified polymers by hydrophobic interactions at the oil-water interface. DCs treated with encapsulated BDS presented a prominent downregulation of costimulatory molecules (CD80, CD83 and MHCII) and upregulation of inhibitory receptors. Moreover, DCs treated with these PUUa NPs-BDS also secreted large amounts of IL-10, a crucial anti-inflammatory cytokine to induce tolerance, and inhibited T lymphocyte activation in a specific manner compared to those cells generated with free BDS. These results demonstrate that PUUa NPs-BDS are a highly specific and efficient system through which to induce DCs with a tolerogenic profile. Given the capacity of PUUa NPs-BDS, this delivery system has a clear advantage for translation to in vivo studies.
Collapse
Affiliation(s)
- Georgina Flórez-Grau
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Pau Rocas
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain
| | - Raquel Cabezón
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | | | - Julián Panés
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain
| | - Josep Rocas
- Nanobiotechnological Polymers Division, Ecopol Tech S.L., Tarragona, Spain
| | - Fernando Albericio
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain; Department of Organic Chemistry, University of Barcelona, Barcelona, Spain; School of Chemistry & Physics, University of Kwazulu-Natal, Durban, South Africa; Networking Centre on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.
| | - Daniel Benítez-Ribas
- Centro de Investigación Biomédica en Red, Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.
| |
Collapse
|